Bioengineered Protein Drugs Market to Reach $685.4 Billion in 2035, Growing at 5.3% CAGR

Bioengineered protein drugs market valued at $412.2 billion in 2025 and is projected to reach $685.4 billion by 2035, growing at a CAGR of 5.3% during the forecast period (2026-2035). The market encompasses biologically engineered therapeutic proteins developed using recombinant DNA technology and advanced bioprocessing techniques to treat a wide range of diseases. The market is witnessing strong global growth driven by the rising prevalence of chronic and life-threatening diseases, increasing adoption of targeted biologics, and continuous advancements in biotechnology and protein engineering. Expansion is further supported by growing investments in biologics R&D, increasing approvals of biosimilars, and the rapid development of next-generation monoclonal antibodies and recombinant vaccines. Pharmaceutical and biotechnology companies are actively expanding manufacturing capacities and biologics pipelines to meet increasing global demand. Additionally, advancements in cell line development, protein expression systems, and large-scale biomanufacturing technologies are significantly enhancing production efficiency and scalability.

Browse the full report description of “Bioengineered Protein Drugs Market Size, Share & Trends Analysis Report by Drug Type (Monoclonal Antibodies, Therapeutic Proteins, and Vaccines), By Indication (Cancer, Diabetes, Autoimmune Diseases, Infectious Diseases, CVD, Neurodegenerative Diseases, and Others) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/bioengineered-protein-drugs-market

According to global health organizations and industry data, the increasing burden of chronic diseases, along with rising demand for precision medicine and immunotherapy, has significantly strengthened the adoption of bioengineered protein drugs. Large-scale clinical datasets, biologics registries, and global disease surveillance systems are playing a critical role in estimating therapeutic demand, optimizing production, and supporting long-term biologics market expansion.

Key Statistics: Bioengineered Protein Drugs at a Glance

• Monoclonal antibodies account for over 60% of total biologics revenue, reflecting their dominant role in targeted therapies, especially in oncology and autoimmune diseases.
• Cancer accounts for nearly 10 million deaths annually worldwide, significantly driving demand for protein-based therapeutics and immunotherapies.
• More than 537 million adults globally are living with diabetes, increasing the need for recombinant insulin and other therapeutic protein drugs.

Key Innovators Driving Bioengineered Protein Drugs Transformation

The key players in the bioengineered protein drugs market include AbbVie Inc., Amgen Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Merck & Co., Inc, among others.

• In June 2025, Amgen Inc. expanded its biologics pipeline by advancing next-generation protein therapeutics focused on oncology and inflammatory diseases, emphasizing improved targeting and extended half-life profiles.
• In April 2025, F. Hoffmann-La Roche Ltd strengthened its bioengineered protein portfolio through advancements in monoclonal antibody and bispecific antibody technologies aimed at enhancing precision treatment outcomes across multiple therapeutic areas.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Drug Type
  • By Indication
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - AbbVie Inc., Amgen Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Merck & Co., Inc, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Bioengineered Protein Drugs Market Report Segment

By Drug Type

• Monoclonal Antibodies
• Therapeutic Proteins
• Vaccines

By Indication

• Cancer
• Diabetes
• Autoimmune Diseases
• Infectious Diseases
• CVD
• Neurodegenerative Diseases
• Others

Global Bioengineered Protein Drugs Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/bioengineered-protein-drugs-market